Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vivo drug r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :NPJ Precis Oncol
Главные авторы: White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302655/
https://ncbi.nlm.nih.gov/pubmed/34302041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00209-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы